A Randomized, Placebo-Controlled, Double-Blind Phase III Study Evaluating the Safety and Efficacy of the Addition of a PARP Inhibitor Plus Carboplatin Versus the Addition of Carboplatin in Combination with Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
Zielgerichtet - Therapieart: neoadjuvant